These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17574479)

  • 1. Parathyroid hormone assay: problems and opportunities.
    Martin KJ; González EA
    Pediatr Nephrol; 2007 Oct; 22(10):1651-4. PubMed ID: 17574479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease.
    Herberth J; Fahrleitner-Pammer A; Obermayer-Pietsch B; Krisper P; Holzer H; Malluche HH; Dobnig H
    Clin Nephrol; 2006 May; 65(5):328-34. PubMed ID: 16724653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy.
    Goodman WG; Jüppner H; Salusky IB; Sherrard DJ
    Kidney Int; 2003 Jan; 63(1):1-11. PubMed ID: 12472763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need for reliable serum parathyroid hormone measurements.
    Torres PU
    Kidney Int; 2006 Jul; 70(2):240-3. PubMed ID: 16838038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parathormone and chronic kidney disease].
    Bacchetta J; Jolivot A; Souberbielle JC; Charrié A; Guebre F; Chauvet C; Fouque D
    Nephrol Ther; 2007 Jul; 3(4):133-8. PubMed ID: 17658439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status?
    Donadio C; Ardini M; Lucchesi A; Donadio E; Cantor T
    Clin Nephrol; 2007 Mar; 67(3):131-9. PubMed ID: 17390737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable parathyroid hormone(1-84)/carboxylterminal PTH ratios detected by 4 novel parathyroid hormone assays.
    Koller H; Zitt E; Staudacher G; Neyer U; Mayer G; Rosenkranz AR
    Clin Nephrol; 2004 May; 61(5):337-43. PubMed ID: 15182128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.
    Lehmann G; Stein G; Hüller M; Schemer R; Ramakrishnan K; Goodman WG
    Kidney Int; 2005 Sep; 68(3):1206-14. PubMed ID: 16105052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
    Cantor T; Sci B
    Nefrologia; 2003; 23 Suppl 2():69-72. PubMed ID: 12778858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTH determination in hemodialyzed patients-A laboratory perspective.
    Cavalier E; Souberbielle JC; Delanaye P
    Semin Dial; 2019 Nov; 32(6):490-492. PubMed ID: 31631422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of assays for parathyroid hormone.
    Goodman WG
    Semin Dial; 2005; 18(4):296-301. PubMed ID: 16076352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-method variability in PTH measurement: implication for the care of CKD patients.
    Souberbielle JC; Boutten A; Carlier MC; Chevenne D; Coumaros G; Lawson-Body E; Massart C; Monge M; Myara J; Parent X; Plouvier E; Houillier P
    Kidney Int; 2006 Jul; 70(2):345-50. PubMed ID: 16788691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoassays for the detection of parathyroid hormone.
    Jüppner H; Potts JT
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N81-6. PubMed ID: 12412782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation.
    Gao P; D'Amour P
    Clin Lab; 2005; 51(1-2):21-9. PubMed ID: 15719701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders.
    Kakuta T; Ishida M; Fukagawa M
    Ther Apher Dial; 2018 Jun; 22(3):220-228. PubMed ID: 29781225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical issues of PTH assays in CKD.
    Komaba H; Goto S; Fukagawa M
    Bone; 2009 Apr; 44(4):666-70. PubMed ID: 19159701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid hormone: new assays, new receptors.
    Martin KJ; Akhtar I; González EA
    Semin Nephrol; 2004 Jan; 24(1):3-9. PubMed ID: 14730504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mechanism for skeletal resistance in uremia.
    Slatopolsky E; Finch J; Clay P; Martin D; Sicard G; Singer G; Gao P; Cantor T; Dusso A
    Kidney Int; 2000 Aug; 58(2):753-61. PubMed ID: 10916099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.
    Coen G; Bonucci E; Ballanti P; Balducci A; Calabria S; Nicolai GA; Fischer MS; Lifrieri F; Manni M; Morosetti M; Moscaritolo E; Sardella D
    Am J Kidney Dis; 2002 Aug; 40(2):348-54. PubMed ID: 12148108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E; Cinotti GA; Fondi G; Manni M; Pasquali M; Perruzza I; Sardella D
    J Lab Clin Med; 1993 Jul; 122(1):103-9. PubMed ID: 8320484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.